Accuro Immunology AB
Karolinska Science Park, Fogdevreten 2, S-171 77 Stockholm, Sweden
E-mail info@accuro.net

 

 

 

News
 

Accuro Immunology have been granted a first European patent on its TEIPP technology. The patent was officially issued on March 19th 2003 and covers commercial applications of the TEIPP technology. Patent applications in US, Japan and other countries are still pending.

Accuro Immunology has selected it's first candidate drug based on TEIPP-01. For further information, see press release.

  

If you have any questions regarding Accuro Immunology's present situation, please contact Director Max Petersson, Ph + 46 70 968 7601, max.petersson@accuro.net.

 

 

 

 

 

ŠAccuro Immunology AB